Products

CorInsights MRI
ADM Diagnostics
Neurology AI
CorInsights MRI is an FDA-cleared software that analyzes standard MRI scans to provide quantitative brain tissue volume measurements, aiding in the assessment of neurodegenerative conditions like Alzheimer's disease.

See all 1 product →

About ADM Diagnostics

ADM Diagnostics, Inc. (ADMdx) is a healthcare AI company dedicated to developing advanced diagnostic tools for neurodegenerative and neuropsychiatric disorders. The company leverages brain imaging techniques, including MRI and PET scans, in conjunction with artificial intelligence (machine learning and pattern recognition) and blood biomarkers. Their proprietary technology aims to provide clinicians with analysis tools for earlier and more accurate identification of conditions such as Alzheimer’s disease, various dementias (e.g., Lewy Body Dementia, Frontotemporal Dementia, Mild Cognitive Impairment), and the effects of repeated head impact, including Chronic Traumatic Encephalopathy (CTE).

ADMdx’s offerings are designed to assist medical professionals in assessing and differentiating brain effects in early, potentially reversible stages, as well as monitoring disease progression. Their FDA-cleared product, CorInsights® MRI, provides quantitative information about brain tissue volume from standard MRI scans, translating these measurements into illustrated reports for radiologists and neurologists. Beyond clinical diagnostics, ADMdx also provides comprehensive imaging Contract Research Organization (CRO) services for central nervous system (CNS) imaging trials, supporting pharmaceutical companies in drug development studies through participant inclusion, stratification, and detection of treatment effects.

The company’s work is built upon a curated database of tens of thousands of well-characterized brain images with associated clinical and biomarker data, and they collaborate with leading researchers in the Traumatic Brain Injury and Alzheimer’s disease fields. Their diagnostic solutions aim to improve patient care, support the development of effective therapeutics, and address the significant challenges posed by neurodegenerative diseases.

Focus Areas

Neuroimaging diagnostic software Alzheimer's disease other dementias traumatic brain injury (TBI) brain imaging artificial intelligence blood biomarkers brain tissue volume quantitation

Business Intelligence

Key InvestorsNational Institutes of Health (NIH), National Institutes of Aging (NIA), National Science Foundation, HHS
PartnershipsCleveland Clinic Lou Ruvo Center for Brain Health, Center for Transformative Neuroscience at the University of Nevada, Boston University Chronic Traumatic Encephalopathy Center, Indiana University, Mount Sinai Icahn School of Medicine, Weill Cornell College of Medicine, The University of Arizona, Rockefeller University
AcquisitionsNone
TechnologyProprietary imaging algorithms, multivariate analysis algorithms, machine learning, AI, Deep Learning, brain imaging, blood biomarkers, cloud-native, PipelineMAX software
FDA Clearances1 cleared products (estimated)

What Physicians Need to Know

Neuroimaging Diagnostics
Specializes in advanced neuroimaging diagnostic software, leveraging standard MRI and PET scans (Amyloid PET, Tau PET, FDG PET) to provide highly accurate and predictive tools for brain disorders. Their CorInsightsu00ae MRI is an FDA 510k cleared product.
Alzheimer's & Dementias
A core focus on early and accurate identification of Alzheimer's disease and other dementias (e.g., Lewy Body Dementia, frontotemporal dementia), addressing challenges of undiagnosed and misdiagnosed cases. They support drug development and patient inclusion in clinical trials for these conditions.
Traumatic Brain Injury (TBI) & CTE
Developing diagnostic tools to detect and differentiate the effects of repeated head impact (TBI) and Chronic Traumatic Encephalopathy (CTE) from Alzheimer's disease, including early and potentially reversible stages.
Artificial Intelligence & Machine Learning
Pioneers in applying AI and Deep Learning to brain imaging, utilizing sophisticated pattern recognition algorithms to identify and quantify complex brain changes. This technology distills numerous data points into numeric scores, offering greater sensitivity and statistical power.
Blood Biomarkers Integration
Combines brain imaging and AI with blood biomarkers to provide comprehensive analysis and differentiate brain effects. They have published work demonstrating relationships between plasma biomarkers and various PET and MRI measures in Alzheimer's patients.
Brain Tissue Volume Quantitation
Offers automated quantification of brain tissue volumes, including hippocampal and white matter lesion volumes, compared to population reference data to improve diagnostic accuracy for dementias.
Physician Tip

ADM Diagnostics stands out for physicians by offering tools that enable earlier and more accurate diagnosis of complex neurodegenerative conditions like Alzheimer's and other dementias, as well as TBI/CTE. Their AI-driven approach provides objective, quantifiable insights from standard MRI and PET scans, making subtle brain changes interpretable for clinical use. This can significantly reduce misdiagnosis rates and support timely intervention and treatment planning. The integration of blood biomarkers with imaging offers a more comprehensive view of patient status, aiding in patient selection for clinical trials and monitoring treatment efficacy. Their FDA 510k cleared CorInsightsu00ae MRI provides advanced reporting using readily available MRI brain scans, streamlining diagnostic workflows and enhancing patient care.

ADM Diagnostics' solutions are designed to work with standard brain imaging modalities (MRI, PET). While specific EHR/EMR integration details are not explicitly provided, the nature of their diagnostic software and reporting (CorInsights reports) suggests a focus on seamless integration into existing clinical workflows to facilitate efficient access to advanced diagnostic insights for medical professionals.

Products by ADM Diagnostics

1 product in the directory

CorInsights MRI
ADM Diagnostics
Neurology AI
CorInsights MRI is an FDA-cleared software that analyzes standard MRI scans to provide quantitative brain tissue volume measurements, aiding in the assessment of neurodegenerative conditions like Alzheimer's disease.

What the Web Says

ADM Diagnostics, certified in December 2020, is a company that provides automated volumetric MRI tools for dementia diagnosis. While the company itself is relatively new to published peer-reviewed validation studies, the broader field of AI medical diagnostic platforms aims to enhance diagnostic accuracy, speed up clinical workflows, and reduce errors by analyzing various medical data. Employer reviews for ADM (Archer Daniels Midland, a different company) show a mixed sentiment regarding work-life balance, pay, and management, with some employees praising benefits and team environment, while others express concerns about workload and communication.

Overall: Mixed

Strengths

  • Great pay and benefits (for ADM, not ADM Diagnostics)
  • Supportive corporate community (for ADM)
  • Varied duties keep employees engaged (for ADM)
  • Thorough and effective interview process (for ADM)
  • Durable device with great features (for ADM 1000 Flowmeter, a product not directly linked to ADM Diagnostics)
  • Easy to use and lightweight product (for ADM 1000 Flowmeter)

Limitations

  • High workload (for ADM)
  • Lack of vertical communication (for ADM)
  • Certain plants being neglected (for ADM)
  • Managers asking for things that cannot happen instantly (for ADM)
  • No respect for work/life balance in some departments (for ADM)
  • Underpaid for the sacrifice (for ADM)

Based on reviews from: Comparably, Indeed.com, Labcompare, PMC

Last updated: 2026-07-17

Videos

News, demos, and interviews about ADM Diagnostics.

Loading videos...

Videos load interactively. If none appear, search YouTube for ADM Diagnostics →

View all on YouTube

Press & Coverage

GlobeNewswire
ADM Diagnostics, Inc. Awarded $1.96 Million Grant From the National Institutes of Health
ADM Diagnostics (ADMdx) received a two-year, $1.96 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Aging (NIA) to develop a diagnostic test for the effects of repeated head impact and to differentiate them from Alzheimer's disease. The project utilizes brain imaging, artificial intelligence, and blood biomarkers.
2022-09
360Dx
ADM Diagnostics Wins $2M NIH Grant for Brain Injury Test Development
ADM Diagnostics has been awarded a National Institutes of Health grant of nearly $2 million to develop a test for traumatic brain injury. This grant will support the development of a diagnostic product to detect and differentiate the effects of repetitive head impact from dementias like Alzheimer's disease.
2022-09
Applied Radiology
ADM Diagnostics Receives NIH Grant to Distinguish Effects of TBI from Alzheimer's Disease
ADM Diagnostics, Inc. (ADMdx) secured a two-year, $1.96 million Phase II SBIR grant from the National Institutes of Aging (NIA) to create a diagnostic test that can identify the effects of repeated head impact on the brain and distinguish them from Alzheimer's disease. The company will use brain imaging, artificial intelligence, and blood biomarkers in this endeavor.
2022-09
ADMdx
ADMdx Awarded New Patent Supporting Disease Diagnosis Using Pattern Analysis
ADMdx has been granted a new patent for a machine learning approach that differentiates brain effect patterns associated with multiple diseases within the same brain scan. This technology aims to address cases where patients may have more than one condition causing cognitive impairment.
2022-06
ADMdx
ADM Diagnostics, Inc. Announces Receipt of 510(k) FDA Clearance for its CorInsightsu00ae MRI Product
ADM Diagnostics, Inc. received FDA 510(k) clearance for its CorInsightsu00ae MRI product, which provides quantitative information about brain tissue volume from standard MRI scans. This tool is intended for use by radiologists, neurologists, and clinical researchers to gain insights into potential causes of cognitive impairment.
2021-12
ADMdx
Results of ADMdx's Visual Read of MK-6240 Tau PET scans Published
ADMdx is a co-lead author on a newly published paper detailing the results of a visual read method for the tau PET tracer MK-6240. This publication describes a method for assessing tau, one of the abnormal proteins associated with Alzheimer's disease.
2023-02
J Nucl Med
The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification
Guidelines established by the Quantitative Imaging Biomarkers Alliance (QIBA) Amyloid PET working group, co-chaired by Dawn Matthews of ADMdx, have been published in the Journal of Nuclear Medicine. The article summarizes multi-year work defining criteria for PET image acquisition and measurement to reduce variability in results.
2023-02
ADMdx
Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in Alzheimer's disease patients
ADMdx collaborated on a study that published work demonstrating relationships between blood biomarkers and brain imaging in patients with Alzheimer's Disease. The publication appeared in the Journal of Neuroscience.
2023-07

Frequently Asked Questions

ADM Diagnostics offers CorInsightsu00ae MRI, an FDA-cleared software that analyzes standard MRI scans to provide quantitative brain tissue volume measurements. This software uses proprietary algorithms and a normative database to assist in assessing neurodegenerative conditions like Alzheimer's disease and other dementias. ADMdx also leverages artificial intelligence in developing diagnostic tools that combine brain imaging and blood biomarkers to differentiate the effects of traumatic brain injury (TBI) from Alzheimer's disease.
CorInsightsu00ae MRI provides quantitative brain tissue volume analysis from standard MRI scans, aiding in the diagnosis and monitoring of Alzheimer's disease and various dementias. Furthermore, ADM Diagnostics is actively developing a diagnostic test, supported by an NIH grant, to detect the effects of repeated head impact (TBI) and accurately differentiate these from Alzheimer's disease using a combination of brain imaging, AI, and blood biomarkers.
ADM Diagnostics integrates blood biomarkers into its research and development, particularly for its diagnostic tool aimed at differentiating TBI effects from Alzheimer's disease. Their CorInsightsu00ae MRI product directly addresses brain tissue volume quantitation concerns by providing automated, quantitative measurements of brain regions, comparing them to a comprehensive normative database to aid in clinical assessment.
ADM Diagnostics' flagship neuroimaging software, CorInsightsu00ae MRI, has received 510(k) FDA clearance. This clearance signifies that the product meets the regulatory requirements for medical devices in the United States, ensuring its safety and effectiveness for clinical use.
ADM Diagnostics collaborates with leading researchers and institutions to advance brain disorder diagnostics and treatment. Key partners include the Cleveland Clinic Lou Ruvo Center for Brain Health, the Boston University Chronic Traumatic Encephalopathy Center, Indiana University, and the Weill Cornell School of Medicine. They also list several prominent academic medical centers as customers and integration partners for CorInsightsu00ae MRI.
For CorInsightsu00ae MRI, ADM Diagnostics aims for a same-day turnaround for patient-specific reports after a standard MRI scan is submitted electronically. They also offer web-based introductions for medical professionals to familiarize them with the product. General inquiries can be made through contact forms on their website.
ADM Diagnostics demonstrates stability through its FDA-cleared product, CorInsightsu00ae MRI, and significant funding, including a multi-million dollar Phase II SBIR grant from the National Institutes of Health. The company also holds patents supporting disease diagnosis using pattern analysis and actively publishes research, indicating ongoing innovation and a strong scientific foundation.

Related Companies

Google DeepMind is a leading artificial intelligence (AI) research laboratory, a subsidiary of Alphabet Inc., dedicated to developing advanced AI systems to benefit humanity. The company focuses on creating general-purpose AI that can learn and solve complex problems, drawing inspiration from neuroscience and machine learning. Their work spans various fields, including healthcare, scientific discovery, and […]

TalkToMedi is a Canadian healthcare AI company that has developed a clinical-grade voice AI platform called MEDI. This platform is designed to automate patient communication and administrative tasks for medical clinics, including family medicine, specialty clinics, allied health, and physiotherapy. MEDI handles high-volume patient calls, automating appointment inquiries, booking, rescheduling, and cancellations based on the […]

Menaela is an AI-first practice management system designed for solo practitioners, small private clinics, and clinic owners. It integrates patient communication, scheduling, CRM, and medical documentation into a single platform, aiming to replace multiple disconnected tools and bots. The system features an AI practice manager that understands natural-language requests, utilizes real clinic data, and performs […]

Avie (avie.me) is a healthcare AI company that focuses on providing a next-generation, whole-person health approach, bridging the gap between clinical and holistic care. The company connects individuals with providers and clinicians who can support their unique physical, emotional, cognitive, and logistical needs. Avie emphasizes fusing physical and mental best practices to enhance overall health, […]

Saile is a physician-founded healthcare technology company that addresses critical inefficiencies in healthcare staffing and credentialing. Their AI-powered platform acts as a “universal credential passport” for physicians, centralizing and managing all medical licenses, certifications, and CME credits in one secure, portable vault. This system aims to significantly reduce the administrative burden and delays associated with […]

Data Capture Experts (DCE) is an Australian-based healthcare AI company that is at the forefront of digital health transformation. They specialize in developing and implementing digital health platforms that integrate data, technology, and human-centered design to create intuitive and connected healthcare systems. Their flagship platform, DC2Vue, is designed to go beyond traditional Electronic Medical Records […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.